Dynavax Initiates Phase 1/2 Study Of Novel Shingles Vaccine Program Evaluating Safety, Tolerability And Immunogenicity Of Z-1018
Portfolio Pulse from Benzinga Newsdesk
Dynavax has initiated a Phase 1/2 study for its novel shingles vaccine, Z-1018, to evaluate its safety, tolerability, and immunogenicity.
June 27, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dynavax has begun a Phase 1/2 clinical trial for its new shingles vaccine, Z-1018. This study will assess the vaccine's safety, tolerability, and immunogenicity, which could lead to significant advancements in their product offerings if successful.
The initiation of a Phase 1/2 study for a new vaccine is a significant milestone for Dynavax. Positive results could lead to further clinical trials and eventual market approval, potentially boosting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100